Search for a Writer:
Calculated Writer Scores
- Frequency of opinion markers: Not set
- Sentiment markers: Not set
- What is this?
Community Writer Scores
Coverage
Words Associated with BRETT SCOTT
Most Frequently Mentioned Topics
Sources They're Writing For (last 60 days)
Writer Feed Widget
Grab this free widget and get the latest news for this writer. You can post it on your web page or blog, or add it to your desktop. Click on the "get & share" button at the bottom.
Articles Written by: BRETT SCOTT
I have based a lot of my analysis on this blog around financial models, specifically rNPV, which I have
talked about many times. However, after a discussion on ViroPharma's
(VPHM) Yahoo! Finance message board, I noticed that I never mentioned a
key ...
From BRETT SCOTT,
ETF Investor,
29 Jan 2008
Amgen (AMGN) reported earnings Thursday night and investors were giving the
stock a 4% boost Friday. The stock, which is down some 36% in the past
year, has struggled since mid-2005. The company's growth has slowed,
and the company has a cloud over it ...
From BRETT SCOTT,
ETF Investor,
28 Jan 2008
Gilead Sciences (GILD) announced a record fourth quarter Wednesday, as
the company posted $1 billion in product sales for the quarter, the
first time the company had broken the billion-dollar mark in product
sales. Led again by its HIV franchise, ...
From BRETT SCOTT,
ETF Investor,
25 Jan 2008
It has been brought to my attention that I made an error in my recent
Tysabri article. The drug Remicade is owned by Johnson & Johnson (JNJ),
which it received in its purchase of Centocor, Inc. Schering-Plough
(SGP) markets the drug outside the United ...
From BRETT SCOTT,
ETF Investor,
23 Jan 2008
The roller-coaster ride that the drug Tysabri has been on over the past
several years hit another high this week as the FDA approved it to
treat Crohn's Disease [CD]. But this approval doesn't necessarily mean
the roller-coaster ride will end for the ...
From BRETT SCOTT,
ETF Investor,
21 Jan 2008
Genentech (DNA) reported full-year 2007 earnings Monday and, while the
company beat on the bottom line and guided 2008 in-line, investors sent
shares down again as its major drugs missed revenue estimates. Shares
of DNA have traditionally traded on the ...
From BRETT SCOTT,
ETF Investor,
15 Jan 2008
ViroPharma (VPHM) had a big week with its stock climbing 20% after
the company announced better-than-anticipated guidance for 2008 sales
of its bacterial infection drug Vancocin. The company expects that 2007
sales of Vancocin were in the guided range ...
From BRETT SCOTT,
ETF Investor,
14 Jan 2008
Theravance (THRX) shareholders will want to mark February 27 on their
calendars, as the FDA announced Thursday that it will meet to review
Theravance's NDA for its drug telavancin. The FDA has already delayed
telavancin's approval once, saying the ...
From BRETT SCOTT,
ETF Investor,
11 Jan 2008
Isis Pharmaceuticals (ISIS) came out as the big winner from the JPMorgan Healthcare Conference as the biotech announced
a licensing deal with Genzyme (GENZ) for its cholesterol drug
mipomersen. The deal marked the end of an auction for the drug in ...
From BRETT SCOTT,
ETF Investor,
9 Jan 2008
However, analysts came out afterward with
bullish sentiment on Revlimid, and Monday Celgene said that Revlimid
likely beat Street estimates for 2007 revenues, and the company upped
its 2008 guidance, which is providing a boost for the stock.
This
news ...
From BRETT SCOTT,
ETF Investor,
7 Jan 2008
